Antje Hoering

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 990 citations · Full text

Medicine, Oncology, Pharmacology +15

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 888 citations

Medicine, Hematology, Oncology +16

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Blood · 2018 · 495 citations · Full text

Medicine, Molecular Biology, Oncology +12

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Leukemia · 2018 · 453 citations · Full text

Medicine, Genetics, Molecular Genetics +17